FirstWord

While Insilico will lead initial discovery and design efforts, Takeda will assume further development responsibilities for selected candidates.

The company's lead candidate is designed to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

At an event on Tuesday, the AI heavyweight said it plans to target "neglected" diseases.

Hong Kong-listed biotech secures modest upfront with sizeable milestone upside after granting Boulevard Bio rights to MTS-128, a trispecific T-cell engager programme.

The Silicon Valley startup has raised $18.6 million in total to rethink how medications get dispensed, verified and delivered.

Wed, Jul 01, 2026 11:52 CETSpermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) ...

Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer1 Jul 2026Colon and Rectal Cancer ESMO Gastrointestinal Cancers Congress 2026Tumours with no c...

Submission builds on the X2 platform’s 20X increase in PET sensitivity to further enhance biologic guidance and expand versatility of SCINTIX therapyHAYWARD, Calif.--(BUSINESS WIRE)-- RefleXion Medica...

The upcoming global debut is set to mark a step forward in AI-powered hematology, advancing the 4th Generation of Hematology AnalysisANAHEIM, Calif. and FRANKFURT, Germany, June 29, 2026 /PRNewswire/ ...

PARIS, FRANCE, June 29, 2026 /EINPresswire.com/ -- Ad Scientiam, a pioneer in the development of clinically validated digital biomarkers, today announced the presentation of highly encouraging interim...